KM
Therapeutic Areas
Acrivon Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ACR-368 (prexasertib) | Multiple high unmet need solid cancer types (ovarian, endometrial, head and neck squamous cell carcinoma) | Phase 2 |
| ACR-2316 | Not specified (likely solid tumors) | Clinical candidate |
| ACR-6840 | Not specified (likely solid tumors) | Development candidate |
Leadership Team at Acrivon Therapeutics
PB
Peter Blume-Jensen
CEO, President, Founder, Chairperson
AD
Adam D. Levy
Chief Financial Officer
MR
Mansoor Raza Mirza
Chief Medical Officer
EG
Erick Gamelin
Chief Development Officer
JO
Jesper Olsen
Academic Co-Founder, Head of Phosphoproteomics
ED
Eric Devroe
Chief Operating Officer
MS
Michail Shipitsin
Head of Biomarker Development
JJ
Joon Jung
Head of Data Science
JV
John van Duzer
Head of Chemistry Manufacturing and Controls